David Fajgenbaum: Repurposing existing drugs for new indications is both faster and less expensive

David Fajgenbaum, Associate Professor of Medicine at University of Pennsylvania School of Medicine, shared on X:

“1 in 10 of us live with a disease without an approved therapy. Even more frightening is that 50-80% of people with rare diseases are children, 30% of whom will not survive until kindergarten.

Repurposing existing drugs for new indications is both faster and less expensive than new drug development and in many cases, the knowledge connecting these drugs to new uses already exists.

Yet, these potential cures sit on pharmacy shelves for decades, underutilized.

At EveryCure, we’re dedicated to unlocking the full potential of these drugs, ensuring that they reach the patients who desperately need them.”

Link to video.
Source: David Fajgenbaum/X